Published: Fri, March 02, 2018
Business | By Kate Woods

The Heron Therapeutics (HRTX) Issues Earnings Results, Misses Estimates By $0.29 EPS

The stock grabbed 28 new institutional investments totaling 1,240,197 shares while 8 institutional investors sold out their entire positions totaling 526,075 shares. The hedge fund run by Brad Farber held 90,000 shares of the health care company at the end of 2017Q3, valued at $1.45M, up from 60,000 at the end of the previous reported quarter. The stock of Heron Therapeutics, Inc.

The stock decreased 0.58% or $0.6 during the last trading session, reaching $102.91.

In the transaction dated January 19, 2017, the great number of shares acquired came courtesy the Director, 10% Owner; Tang Kevin C added a total of 2,459,016 shares at an average price of $12.2, amounting to approximately $29,999,995. It has underperformed by 37.62% the S&P500.

More news: Press standards inquiry axed by United Kingdom government ministers

Eastern Bank increased its stake in Hologic (HOLX) by 34.64% based on its latest 2017Q3 regulatory filing with the SEC. Following the completion of the sale, the vice president now directly owns 7,584 shares in the company, valued at $151,680.

In related news, VP Kimberly Manhard sold 7,584 shares of the company's stock in a transaction on Wednesday, January 10th. Carlisle Companies had 27 analyst reports since September 1, 2015 according to SRatingsIntel. The stock increased 1.97% or $0.4 during the last trading session, reaching $20.75. Throughout the trading on 02/28/2018, the share price floated between $20.05 and $21.95. It is down 0.00% since February 28, 2017 and is. Nawana Namal bought $250,023 worth of Hologic, Inc. The company was upgraded on Tuesday, February 13 by Edward Jones.

Investors sentiment decreased to 0.88 in Q3 2017. Its down 0.05, from 0.86 in 2017Q2. It dropped, as 75 investors sold HOLX shares while 145 reduced holdings. Sequoia Ltd Com reported 3,863 shares stake. Credit Agricole S A invested in 660,876 shares or 0.57% of the stock. (NASDAQ:HOLX) for 66,619 shares. Buckingham Asset Mngmt Ltd Com holds 14,576 shares or 0.88% of its portfolio. (NASDAQ:HOLX) for 16,272 shares. Rowland Invest Counsel Adv owns 2,322 shares or 0.19% of their United States portfolio. Metropolitan Life Ny accumulated 288,099 shares or 0.46% of the stock. 20,876 were reported by Norinchukin Bank & Trust The. Stockbridge Limited Liability Company has 5.50M shares. Hall Laurie J Trustee has invested 0.06% in Hologic, Inc.

More news: Brokers Offer Predictions for Federal Realty Investment Trust's Q1 2018 Earnings (FRT)

Crocs, Inc. (NASDAQ:CROX) is worth US$981.66 Million and has recently fallen -4.09% to US$14.07.

Similar statistics are true for the second largest owner, Tang Capital Management Llc, which owns 8,466,377 shares of the stock are valued at $186.68 million. BidaskClub raised Heron Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, February 15th. Therefore 58% are positive. Boeing had 104 analyst reports since August 26, 2015 according to SRatingsIntel. The stock of Hologic, Inc. The firm has "Buy" rating given on Friday, November 10 by Noble Financial. Raymond James maintained it with "Buy" rating and $44.0 target in Friday, December 1 report. The firm earned "Hold" rating on Thursday, August 3 by Jefferies. Needham downgraded Hologic, Inc. The firm has "Hold" rating by Canaccord Genuity given on Friday, April 28. The rating was initiated by Lake Street on Thursday, December 10 with "Buy". Deutsche Bank downgraded Hologic, Inc. Out of rating recommendations 0 have given the stock a Buy while 0 recommend the stock as Outperform. Heron Therapeutics, Inc. (NASDAQ:HRTX) has declined 20.92% since March 2, 2017 and is downtrending. Therefore 100% are positive. Mizuho restated a "buy" rating and set a $28.00 price target on shares of Heron Therapeutics in a report on Friday, December 8th. The firm has "Underweight" rating by Barclays Capital given on Wednesday, October 7. The stock hit its 52-week high price on 01/23/18, and 52-week low price on 06/21/17. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.13 average brokerage recommendation. The rating was maintained by FBR Capital on Thursday, February 2 with "Mkt Perform". Heron Therapeutics now has a consensus rating of "Buy" and an average target price of $30.09. The company has an average rating of "Buy" and an average price target of $30.09. As per Tuesday, August 15, the company rating was maintained by Jefferies. After a recent check, Celldex Therapeutics, Inc.'s 14-day RSI is presently at 32.14. (NASDAQ:HRTX) is a huge mover today! Jefferies has "Buy" rating and $20000 target. They set an "outperform" rating and a $22.00 target price on the stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

More news: Walker Found Guilty Of Lesser Charge Of Criminally Negligent Homicide

Like this: